Fu's subcutaneous needling for non-acute idiopathic facial paralysis : a randomized controlled trial.
10.13703/j.0255-2930.20240611-k0001
- Author:
Lamei TAO
1
;
Jing LI
1
;
Jin LU
1
;
Maohui ZHU
2
;
Zhihong XIE
3
;
Xiaoli BAO
4
;
Xinghao DING
5
Author Information
1. Department of Acupuncture and Moxibustion, Nanjing Hospital of TCM Affiliated to Nanjing University of Chinese Medicine/Nanjing Hospital of TCM, Nanjing 210022, Jiangsu Province, China.
2. Department of Rehabilitation, Nanjing Pukou District Hospital of TCM.
3. Second Department of Acupuncture and Moxibustion, Chuzhou City Hospital of Integrated Traditional Chinese and Western Medicine.
4. Nanjing University of Chinese Medicine.
5. Department of Acupuncture and Moxibustion, Nanjing Jing'an Community Health Service Center.
- Publication Type:English Abstract
- Keywords:
Fu's subcutaneous needling;
idiopathic facial paralysis, non-acute phase;
randomized controlled trial (RCT);
reperfusion activity
- MeSH:
Humans;
Male;
Female;
Middle Aged;
Adult;
Acupuncture Therapy;
Aged;
Facial Paralysis/physiopathology*;
Young Adult;
Nitric Oxide/blood*;
Treatment Outcome;
Acupuncture Points;
Endothelins/blood*;
Adolescent
- From:
Chinese Acupuncture & Moxibustion
2024;44(11):1249-1253
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the effect of Fu's subcutaneous needling in the treatment of non-acute idiopathic facial paralysis and its effect on serum levels of nitric oxide (NO) and endothelin (ET).
METHODS:A total of 76 patients with non-acute idiopathic facial paralysis were randomly divided into an observation group (38 cases, 2 cases dropped out) and a control group (38 cases, 2 cases dropped out). The patients in the control group received basic treatment (mecobalamin tablets orally, specific electromagnetic spectrum irradiation, facial muscle rehabilitation training). The patients in the observation group were treated with Fu's subcutaneous needling on the basis of the control group. The needling points included brachioradialis muscle, sternocleidomastoid muscle, trapezius muscle, etc., and the needling was inserted around the affected muscle, and the reperfusion activity was carried out at the same time, once every other day, 3 times a week. Both groups were treated for 4 weeks. The House-Brackmann (H-B) grade and H-B symptom score were observed before treatment, after 2 and 4 weeks of treatment in the two groups. The facial disability index (FDI) score [including physical function (FDIP) score and social life function (FDIS) score] and the serum levels of NO and ET were compared before and after 4 weeks of treatment in the two groups. The clinical effect and safety of the two groups were assessed.
RESULTS:After 2 and 4 weeks of treatment, the H-B grade of the two groups was lower than that before treatment, and the H-B symptom scores were higher than those before treatment (P<0.001, P<0.05); the H-B grade of the observation group was lower than that of the control group, and the H-B symptom score was higher than that of the control group (P<0.01, P<0.05). After 4 weeks of treatment, the FDIP scores of the two groups were higher than those before treatment, and the FDIS scores were lower than those before treatment (P<0.05 ); the FDIP score of the observation group was higher than that of the control group, and the FDIS score was lower than that of the control group (P<0.05). After 4 weeks of treatment, the serum level of NO in the observation group was higher than that before treatment, and the serum level of ET was lower than that before treatment (P<0.05); the increase of serum level of NO and the decrease of serum level of ET in the observation group were greater than those in the control group (P<0.05). The cure rate of the observation group was 55.6% (20/36), which was higher than 22.2% (8/36) of the control group (P<0.05). There were no serious adverse reactions in both groups.
CONCLUSION:Fu's subcutaneous needling combined with basic treatment can effectively improve the motor function of facial muscles in patients with non-acute idiopathic facial paralysis, which may be related to the regulation of serum NO and ET levels.
